Remissão da asma é possível! Conheça os critérios: uma revisão integrativa

Matheus Fonseca Aarestrup; José Otavio Amaral Correa; Fernando Monteiro Aarestrup

doi:10.4322/2526-5393.18051106

Artigo de Revisão

Remissão da asma é possível! Conheça os critérios: uma revisão integrativa

Asthma remission is possible! Learn about the criteria: an integrative review

Matheus Fonseca Aarestrup, José Otavio Amaral Correa, Fernando Monteiro Aarestrup

http://dx.doi.org/10.4322/2526-5393.18051106 Arq Asma Alerg Imunol, vol.10, n1, e18051106, 2026

PDF

Downloads: 0

Resumo

Introdução: Entendido como ausência ou mínima atividade da doença por período prolongado, sem equivaler a cura, o conceito de remissão já é amplamente utilizado em áreas como reumatologia e oncologia. Nos últimos anos, com a evolução do arsenal terapêutico disponível, liderados pelos imunobiológicos, o conceito de remissão na asma ganhou força, apoiado por consensos e artigos científicos, que ao definirem os critérios de remissão, nos trazem novas metas terapêuticas mais ambiciosas e desafiadoras Métodos: Realizou-se uma revisão integrativa da literatura, conduzida segundo o arcabouço de Whittemore & Knafl e relatada conforme itens relevantes do PRISMA 2020. Foram pesquisadas as bases PubMed/MEDLINE, Scopus e Web of Science (01/2019-12/2025. Incluíram-se documentos em inglês de sociedades e painéis de especialistas que propunham definições de remissão da asma Objetivo: O objetivo principal desta revisão é apresentar os critérios de remissão da asma existentes e avaliar sua utilização como meta terapêutica dentro de uma estratégia de cuidado centrado no paciente. Discussão: A adoção de critérios de remissão em asma representa o próximo passo na evolução do cuidado centrado no paciente, alinhando a especialidade ao paradigma treat-to-target já consolidado outras áreas. Na asma, os consensos recentes convergem ao propor critérios clínicos factíveis ao qual se pode agregar critérios biológicos, quando disponível. Conclusão: A remissão emerge como objetivo factível na era dos imunobiológicos, devendo ser perseguida com estratégias individualizadas, centradas no paciente e orientada por medicina de precisão.

Palavras-chave

Asma; indução de remissão; consenso.

Abstract

Introduction: Understood as the absence or minimal activity of disease over a prolonged period, without being equivalent to cure, the concept of remission is already widely used in fields such as rheumatology and oncology. In recent years, with the expansion of the therapeutic armamentarium, led by biologic agents, the concept of remission in asthma has gained strength, supported by consensus documents and scientific articles which, by defining remission criteria, provide new, more ambitious and challenging therapeutic goals. Methods: An integrative review of the literature was conducted, following the framework proposed by Whittemore and Knafl and reported according to the relevant items of PRISMA 2020. The PubMed/MEDLINE, Scopus and Web of Science databases (01/2019-12/2025) were searched. We included English-language documents from societies and expert panels that proposed definitions of asthma remission. Objective: The main objective of this review is to present the existing criteria for asthma remission and to assess their use as a therapeutic target within a comprehensive, patient-centered care strategy. Discussion: The adoption of remission criteria in asthma represents the next step in the evolution of patient-centered care, aligning the specialty with the treat-to-target paradigm already established in other fields. In asthma, recent consensus documents converge in proposing feasible clinical criteria to which biological criteria can be added, when available. Conclusion: Remission is emerging as an achievable goal in the era of biologics and should be pursued through individualized, patientcentered strategies guided by precision medicine.

Keywords

Asthma; remission induction; consensus.

References

1. Global Initiative for Asthma. Global strategy for asthma management and prevention: 2025 update [Internet]. 2025 [citado 2026 dez 9]. https://ginasthma.org/2025-gina-strategy-report/

2. Cox L, Li JT, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120(3, Suppl):S25-85. https://doi.org/10.1016/j.jaci.2007.06.019. PMid:17765078.

3. Diamant Z, van Maaren M, Muraro A, Jesenak M, Striz I. Allergen immunotherapy for allergic asthma: the future seems bright. Respir Med. 2023;210:107125. https://doi.org/10.1016/j.rmed.2023.107125. PMid:36702170.

4. Oberle AJ, Abbas F, Adrish M, Agache I, Conroy M, Coz Yataco A et al. Biologic management in severe asthma for adults: an American college of chest physicians clinical practice guideline. Chest. 2026;169(2):336-48. https://doi.org/10.1016/j.chest.2025.08.042. PMid:41005695.

5. Canonica GW, Varricchi G, Paoletti G, Heffler E, Virchow JC. Advancing precision medicine in asthma: evolution of treatment outcomes. J Allergy Clin Immunol. 2023;152(4):835-40. https://doi.org/10.1016/j.jaci.2023.07.009. PMid:37531979.

6. Nannini LJ. Treat to target approach for asthma. J Asthma. 2020 mar 23;57(6):687-90. https://doi.org/10.1080/02770903.2019.1591443. PMid:30907188.

7. Couillard S, Pavord I, Hoyte F, Siddiqui S, Martin N, Menzies-Gow A et al. “Treat-to-target”: a call for earlier targeted intervention in asthma. J Allergy Clin Immunol Pract. 2025;13(7):1553-8. https://doi.org/10.1016/j.jaip.2025.05.012. PMid:40373871.

8. Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60(5):2102583. https://doi.org/10.1183/13993003.02583-2021. PMid:35361633.

9. Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757-65. https://doi.org/10.1016/j.jaci.2019.12.006. PMid:31866436.

10. Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P et al. Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus. J Allergy Clin Immunol Pract. 2023;11(12):3629-37. https://doi.org/10.1016/j.jaip.2023.07.041. PMid:37558162.

11. Blaiss M, Oppenheimer J, Corbett M, Bacharier L, Bernstein J, Carr T et al. Consensus of an american college of allergy, asthma, and immunology, american academy of allergy, asthma, and immunology, and american thoracic society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131(6):782-5. https://doi.org/10.1016/j.anai.2023.08.609. PMid:37690606.

12. Álvarez-Gutiérrez FJ, Casas-Maldonado F, Soto-Campos G, Blanco-Aparicio M, Delgado J, Padilla Galo A et al. Spanish consensus on remission in asthma (REMAS). Arch Bronconeumol. 2024;60(8):503-9. https://doi.org/10.1016/j.arbres.2024.04.002. PMid:38697903.

13. Miralles-López JC, Alvarez-Gutiérrez FJ, Delgado-Romero J, Quirce S, Soto-Campos JG, Andújar-Espinosa R et al. Disease modification in asthma: are we on the right way? A multidisciplinary expert Delphi consensus (MODIASTHMA Consensus). J Asthma Allergy. 2024;17(14):1163-71. https://doi.org/10.2147/JAA.S488764. PMid:39558970.

14. Shin SH, Choi JY, Yoon J, Kim Y, Jang JG, Moon JY et al. Consensus of Korean Asthma study group on definition of clinical remission in severe asthma: a modified Delphi study. Tuberc Respir Dis. 2026 abr;89(2):215-25. PMid:41362087.

15. Nagase H, Harada N, Tezuka J, Futamura M, Nagao M, Takizawa T et al. Consensus definition of clinical remission in asthma for the Japanese asthma prevention and management guidelines (JGL 2024): a modified Delphi survey and comprehensive review. Allergol Int. 2026;75(1):3-14. https://doi.org/10.1016/j.alit.2025.11.004. PMid:41350127.

16. Jesenak M, Bobcakova A, Djukanovic R, Gaga M, Hanania NA, Heaney LG et al. Promoting prevention and targeting remission of asthma: a EUFOREA consensus statement on raising the bar in asthma care. Chest. 2025;167(4):956-74. https://doi.org/10.1016/j.chest.2024.11.035. PMid:39672229.

17. Pérez-de-Llano L, Veiga-Teijeiro I, Dacal-Rivas D. Contribution of the remission concept to the treatment of asthma. Arch Bronconeumol. 2023;59(9):550-1. https://doi.org/10.1016/j.arbres.2023.03.009. PMid:37005151.

18. Lommatzsch M. Remission in asthma. Curr Opin Pulm Med. 2024;30(3):325-9. https://doi.org/10.1097/MCP.0000000000001068. PMid:38441430.

19. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573-86. https://doi.org/10.1002/art.30129. PMid:21294106.

20. Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology. 2012;51(Suppl 6):16-20. https://doi.org/10.1093/rheumatology/
kes281. PMid:23221582.

21. Studenic P, Aletaha D, de Wit M, Stamm T, Alasti F, Lacaille D et al. Revision of the ACR/EULAR remission criteria for rheumatoid arthritis. Arthritis Rheumatol. 2023;75(1):15-22. https://doi.org/10.1002/art.42347.

22. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7. https://doi.org/10.1136/ard.2009.123919. PMid:20215140.

23. Cardiel MH. Estrategia “treat-t target” en la artritis reumatoide: beneficios reales. Reumatol Clin. 2013;9(2):101-5. https://doi.org/10.1016/j.reuma.2012.04.004. PMid:22985804.

24. Mosnaim G, Carrasquel M, Snedden M, Oppenheimer J, Lang D, Rathkopf M. Patient-reported outcomes in asthma. J Allergy Clin Immunol Pract. 2024;12(10):2562-72. https://doi.org/10.1016/j.jaip.2024.04.061. PMid:38796101.

25. Worth A, Hammersley V, Knibb R, Flokstra-de-Blok B, DunnGalvin A, Walker S et al. Patient-reported outcome measures for asthma: a systematic review. NPJ Prim Care Respir Med. 2014;24:14020. https://doi.org/10.1038/npjpcrm.2014.20.

26. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-7. https://doi.org/10.1034/j.1399-3003.1999.14d29.x. PMid:10573240.

27. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124(4):719-23.e1. https://doi.org/10.1016/j.jaci.2009.06.053. PMid:19767070.

28. Beuther DA, Murphy KR, Zeiger RS, Wise RA, McCann W, Reibman J et al. The asthma impairment and risk questionnaire (AIRQ) control level predict future risk of asthma exacerbations. J Allergy Clin Immunol Pract. 2022;10(12):3204-12.e2. https://doi.org/10.1016/j.jaip.2022.08.017. PMid:35998877.

29. Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546-53. https://doi.org/10.1111/j.1365-2648.2005.03621.x. PMid:16268861.

30. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:271. PMid:33782057.

31. Aarestrup MF, Aarestrup FM, Corrêa JOA. Asthma remission is possible! Understanding the criteria: an integrative review [Internet]. OSF; 2025 [citado 2026 dez 9]. https://archive.org/details/osfregistrations-8enck-v1

32. Vervier J, Guissard F, Henket M, Calmes D, Wirth C, Louis R et al. Concept de rémission dans l’asthme sévère. Rev Med Liege. 2024;79(4):241-7. PMid:38602212.

Submitted date:
10/08/2025

Accepted date:
02/25/2026